The amount of unfolded proteins is
increased in cancer cells, leading
to endoplasmic reticulum (ER) stress. Therefore, cancer cells are
sensitive to drugs capable of further enhancing ER stress. Examples
of such drugs include the clinically approved proteosome inhibitors
bortezomib and carfilzomib. Unfortunately, the known ER stress inducers
exhibit dose-limiting side effects that justify the search for better,
more cancer-specific drugs of this type. Herein, we report on FeC 2, which binds to unfolded proteins prevents their further
processing, thereby leading to ER stress and ROS increase in cancer
cells, but not in normal cells. FeC 2 exhibits low micromolar
toxicity toward human acute promyelocytic leukemia HL-60, Burkitt’s
lymphoma BL-2, T-cell leukemia Jurkat, ovarian carcinoma A2780, lung
cancer SK-MES-1, and murine lung cancer LLC1 cells. Due to the cancer-specific
mode of action, 2 is not toxic in vivo up to the dose
of 147 mg/kg, does not affect normal blood and bone marrow cells at
the therapeutically active dose, but strongly suppresses both primary
tumor growth (confirmed in Nemeth-Kellner lymphoma and LLC1 lung cancer
models of murine tumor) and spreading of metastases (LLC1).